Historically, biotech companies have offered investors the possibility of outsized success, but they also carry high levels of risk. The reason for this is that biotech companies traditionally race to develop cutting edge products. When a product in a biotech company's pipeline fails to materialize or to produce the desired results, that company's stock price can suffer the consequences.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,